Galux
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- IT, information
Our AI-driven platform, GaluxDesign, is built on first principles and de novo designs functional proteins with precision and versatility. We are one of the few companies worldwide that have demonstrated true de novo design of epitope-specific antibodies (link), widely regarded as the most challenging and valuable frontier in AI-driven protein design. This core capability positions GaluxDesign to tackle design challenges across protein modalities, including multi-specific antibodies, VHHs, mini-proteins, and novel protein scaffolds, while simultaneously optimizing multiple molecular properties. Validated through fifteen industry and academic collaborations, GaluxDesign underpins an expanding internal pipeline in oncology, immunology, and metabolic diseases.
Address
SeoulSouth Korea
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}